Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs SGHT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGHT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
SGHT Overall Winner
6-Pillar Tally: MXCT 1 – 4 SGHT (1 Tie)
Matrix Metrics: MXCT 2 – 6 SGHT
As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas SGHT carries 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin).
- Growth vs. Quality Trade-Off: SGHT earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MXCT 41.7/100 SELL) and 1.09β · 48% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs SGHT
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
SGHT
Head-to-Head Winner
Sight Sciences, Inc. Common Stock
$10.18
-4.14% 1D
Market Cap
$590.2M
TTM Revenue
$88M
Forward P/E
N/M
Beta / 30D Vol
1.09β · 48% Vol
Unified Composite Score
53.2
HOLD
Tech 39.0
Fund 54.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 4 SGHT)
1. Valuation Multiples
MXCT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
6.3x
2. Growth & Scale
SGHT
Revenue Growth (YoY)
+48.7%
+25.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$34M
$88M
Market Cap
$132.2M
$590.2M
3. Profitability & Quality
SGHT
Gross Margin
81.0%
87.7%
Operating Margin
-85.5%
-20.2%
Net Profit Margin
-81.4%
-32.1%
Return on Equity (ROE)
-16.9%
-50.1%
4. Balance Sheet & Cash Flow
SGHT
Cash Generation (TTM)
-$24M
-$17M
Cash Flow Margin
-69.2%
-19.1%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$35M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGHT
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
78.7% (8th %ile)
Put/Call OI Skew
N/A
0.01x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (2) vs SGHT (6)| Institutional Metric | MXCT | SGHT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $590.2M | SGHT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +48.7% | +25.2% | MXCT | |
| Operating Margin (TTM) | -85.5% | -20.2% | SGHT | |
| Net Profit Margin | -81.4% | -32.1% | SGHT | |
| Return on Equity (ROE) | -16.9% | -50.1% | MXCT | |
| 52-Week Range Position | 63% ($1–$2) | 83% ($3–$12) | SGHT | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 1.09β · 48% Vol | SGHT | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 53.2 / 100 (HOLD) | SGHT | |
| Trailing 12M Revenue (USD) | $34M | $88M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 87.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · 6.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | -$17M ($35M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SGHT +16.19 pp
3M Horizon
SGHT +22.92 pp
6M Horizon
SGHT +70.66 pp
1Y Horizon
SGHT +66.31 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | SGHT Revenue | MXCT Op. Margin | SGHT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -93.7% | N/A | MXCT |
| FY2020 | $20M | $30M | -71.6% | -116.5% | MXCT |
| FY2021 | $20M | $50M | -84.3% | -105.2% | MXCT |
| FY2022 | $30M | $70M | -95.2% | -117.7% | MXCT |
| FY2023 | $20M | $80M | -247.7% | -70.7% | SGHT |
| FY2024 | $20M | $80M | -230.5% | -63.3% | SGHT |
| FY2025 | $20M | $80M | -247.6% | -48.0% | SGHT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SGHT
CONSOLIDATION
Current IV
78.7%
IV Percentile
8th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SGHT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs SGHT Key Questions & Quantitative Answers
As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas SGHT carries 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin). Growth vs. Quality Trade-Off: SGHT earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MXCT 41.7/100 SELL) and 1.09β · 48% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
SGHT leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with SGHT at +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while SGHT shifted +166.7%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGHT.
MXCT screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.3x EV/Revenue (-19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus SGHT (-50.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SGHT vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs TMCI
· Sector Peer
MXCT vs RLYB
· Sector Peer
SGHT vs CTKB
· Sector Peer
SGHT vs TMCI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem